| B-cell depletion with rituximab in relapsing–remitting multiple sclerosis SL Hauser, E Waubant, DL Arnold, T Vollmer, J Antel, RJ Fox, A Bar-Or, ... New England Journal of Medicine 358 (7), 676-688, 2008 | 2151 | 2008 |
| Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis R Gold, L Kappos, DL Arnold, A Bar-Or, G Giovannoni, K Selmaj, ... New England Journal of Medicine 367 (12), 1098-1107, 2012 | 1502 | 2012 |
| Ocrelizumab versus placebo in primary progressive multiple sclerosis X Montalban, SL Hauser, L Kappos, DL Arnold, A Bar-Or, G Comi, ... New England Journal of Medicine 376 (3), 209-220, 2017 | 956 | 2017 |
| Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis SL Hauser, A Bar-Or, G Comi, G Giovannoni, HP Hartung, B Hemmer, ... New England Journal of Medicine 376 (3), 221-234, 2017 | 848 | 2017 |
| IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases P Shen, T Roch, V Lampropoulou, RA O’Connor, U Stervbo, E Hilgenberg, ... Nature 507 (7492), 366-370, 2014 | 747 | 2014 |
| Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial L Kappos, D Li, PA Calabresi, P O'Connor, A Bar-Or, F Barkhof, M Yin, ... The Lancet 378 (9805), 1779-1787, 2011 | 715 | 2011 |
| Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis M Duddy, M Niino, F Adatia, S Hebert, M Freedman, H Atkins, HJ Kim, ... The Journal of Immunology 178 (10), 6092-6099, 2007 | 580 | 2007 |
| B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6–producing B cells TA Barr, P Shen, S Brown, V Lampropoulou, T Roch, S Lawrie, B Fan, ... Journal of Experimental Medicine 209 (5), 1001-1010, 2012 | 507 | 2012 |
| Rituximab in relapsing‐remitting multiple sclerosis: a 72‐week, open‐label, phase I trial A Bar‐Or, PAJ Calabresi, D Arnold, C Markowitz, S Shafer, LH Kasper, ... Annals of neurology 63 (3), 395-400, 2008 | 464 | 2008 |
| Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays PJ Waters, A McKeon, MI Leite, S Rajasekharan, VA Lennon, A Villalobos, ... Neurology 78 (9), 665-671, 2012 | 430 | 2012 |
| Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions B Banwell, A Ghezzi, A Bar-Or, Y Mikaeloff, M Tardieu The Lancet Neurology 6 (10), 887-902, 2007 | 428 | 2007 |
| A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis JM Burton, S Kimball, R Vieth, A Bar-Or, HM Dosch, R Cheung, D Gagne, ... Neurology 74 (23), 1852-1859, 2010 | 410 | 2010 |
| A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses PW O’connor, D Li, MS Freedman, A Bar-Or, GPA Rice, C Confavreux, ... Neurology 66 (6), 894-900, 2006 | 404 | 2006 |
| Abnormal B‐cell cytokine responses a trigger of T‐cell–mediated disease in MS? A Bar‐Or, L Fawaz, B Fan, PJ Darlington, A Rieger, C Ghorayeb, ... Annals of neurology 67 (4), 452-461, 2010 | 398 | 2010 |
| Comparison of polarization properties of human adult microglia and blood‐derived macrophages BA Durafourt, CS Moore, DA Zammit, TA Johnson, F Zaguia, MC Guiot, ... Glia 60 (5), 717-727, 2012 | 394 | 2012 |
| Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis A Bar‐Or, RK Nuttall, M Duddy, A Alter, HJ Kim, I Ifergan, CJ Pennington, ... Brain 126 (12), 2738-2749, 2003 | 383 | 2003 |
| Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer disease A Monsonego, V Zota, A Karni, JI Krieger, A Bar-Or, G Bitan, AE Budson, ... The Journal of clinical investigation 112 (3), 415-422, 2003 | 363 | 2003 |
| Distinct profiles of human B cell effector cytokines: a role in immune regulation? ME Duddy, A Alter, A Bar-Or The Journal of Immunology 172 (6), 3422-3427, 2004 | 360 | 2004 |
| Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study L Kappos, A Bar-Or, BAC Cree, RJ Fox, G Giovannoni, R Gold, ... The Lancet 391 (10127), 1263-1273, 2018 | 351 | 2018 |
| Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study B Banwell, L Krupp, J Kennedy, R Tellier, S Tenembaum, J Ness, ... The Lancet Neurology 6 (9), 773-781, 2007 | 340 | 2007 |
Ludwig KapposUniversity Hospital BaselEmail verificata su uhbs.ch
